BlossomHill Therapeutics/$BLSM

1D1W1MYTD1Y5YMAX

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
Ticker
$BLSM
Sector
Health
Primary listing
NASDAQ
Employees
63
Headquarters
San Diego, United States
Website
bhtherapeutics.com

BLSM Metrics

BasicAdvanced
$774M
-
-$31.83
-
-

What the Analysts think about BLSM

Analyst ratings (Buy, Hold, Sell) for BlossomHill Therapeutics stock.
Analyst projections of the future price of BlossomHill Therapeutics stock.

Bulls say / Bears say

BH-30643 produced a 45% objective response rate and 88% disease-control rate in 40 patients with EGFR C797S-positive NSCLC, while 63% remained on treatment at a median follow-up of 6.9 months. The signal came from a heavily pre-treated group with few targeted options and a reported favourable safety profile. (GlobeNewswire)
The FDA granted BH-30643 Fast Track designation for advanced or metastatic EGFR C797S-positive NSCLC after third-generation TKI treatment. BlossomHill plans an end-of-Phase-1 FDA meeting in late 2026 and a global Phase 2 study in the first quarter of 2027, creating clear near-term catalysts. (MarketChameleon, BlossomHill Therapeutics)
BH-30236 gives BlossomHill a second clinical programme rather than leaving investors wholly dependent on the EGFR asset. Early Phase 1/1b data in relapsed or refractory AML and higher-risk MDS showed safety findings and initial signs of anti-leukaemic activity both alone and with venetoclax. (BlossomHill Therapeutics, BioSpace)
The headline BH-30643 result is still preliminary: it comes from only 40 patients, median follow-up was 6.9 months and median response duration had not matured. The Phase 1/2 trial is still enrolling, so longer follow-up and a larger dataset could materially change the efficacy or safety picture. (MedPath Trial, GlobeNewswire)
BlossomHill has no product revenue, reported a $23.8 million second-quarter loss and used $44.2 million of cash in the first six months. Management forecasts funding into the second quarter of 2028, but the 10-Q warns that this estimate may prove wrong and that future fundraising could dilute shareholders. (StockTitan, BlossomHill Therapeutics)
BH-30643 is entering a more competitive EGFR market: AstraZeneca has backed Dizal’s competing broad EGFR inhibitor, giving a large oncology incumbent exposure to a similar opportunity. That could make differentiation, trial recruitment and eventual commercial uptake harder for BlossomHill. (ApexOnco, BlossomHill Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.

BLSM Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

BLSM Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.